Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3B study of hydroxyprogesterone caproate injection to prevent recurrent preterm birth
2009-014696-52Phase 3Completed
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in preterm birth comparing Hydroxyprogesterone caproate arm with Vehicle (placebo) arm (2 arms). Primary endpoint: Co-primary outcomes. Started Nov 2009; status: completed.
02
Drugs
hydroxyprogesterone caproate
03
Conditions
preterm birth
Beyond the preview
Go deeper on 2009-014696-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014696-52.